Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 33

1.

Cost analysis of colorectal cancer screening with CT colonography in Italy.

Mantellini P, Lippi G, Sali L, Grazzini G, Delsanto S, Mallardi B, Falchini M, Castiglione G, Carozzi FM, Mascalchi M, Milani S, Ventura L, Zappa M.

Eur J Health Econ. 2017 Jul 5. doi: 10.1007/s10198-017-0917-3. [Epub ahead of print]

PMID:
28681075
2.

Multimodal lung cancer screening using the ITALUNG biomarker panel and low dose computed tomography. Results of the ITALUNG biomarker study.

Carozzi FM, Bisanzi S, Carrozzi L, Falaschi F, Lopes Pegna A, Mascalchi M, Picozzi G, Peluso M, Sani C, Greco L, Ocello C, Paci E; ITALUNG Working Group.

Int J Cancer. 2017 Jul 1;141(1):94-101. doi: 10.1002/ijc.30727. Epub 2017 Apr 21.

PMID:
28387927
3.

Mortality, survival and incidence rates in the ITALUNG randomised lung cancer screening trial.

Paci E, Puliti D, Lopes Pegna A, Carrozzi L, Picozzi G, Falaschi F, Pistelli F, Aquilini F, Ocello C, Zappa M, Carozzi FM, Mascalchi M; and the ITALUNG Working Group.

Thorax. 2017 Sep;72(9):825-831. doi: 10.1136/thoraxjnl-2016-209825. Epub 2017 Apr 4.

PMID:
28377492
4.

Interobserver reproducibility of cytologic p16INK4a /Ki-67 dual immunostaining in human papillomavirus-positive women.

Benevolo M, Allia E, Gustinucci D, Rollo F, Bulletti S, Cesarini E, Passamonti B, Giovagnoli MR, Carico E, Carozzi FM, Mongia A, Fantacci G, Confortini M, Rubino T, Fodero C, Prandi S, Marchi N, Farruggio A, Coccia A, Macrì L, Ghiringhello B, Ronco G, Bragantini E, Polla E, Maccallini V, Negri G, Giorgi Rossi P; New Technologies for Cervical Cancer Screening 2 (NTCC2) Working Group.

Cancer. 2017 Mar;125(3):212-220. doi: 10.1002/cncy.21800. Epub 2016 Dec 7.

PMID:
27926800
5.

Effectiveness of HPV vaccination in women reaching screening age in Italy.

Carozzi FM, Ocello C, Burroni E, Faust H, Zappa M, Paci E, Iossa A, Bonanni P, Confortini M, Sani C.

J Clin Virol. 2016 Nov;84:74-81. doi: 10.1016/j.jcv.2016.09.011. Epub 2016 Oct 3.

PMID:
27728850
6.

GISCi: an opportunity for more consideration and visibility for young researchers.

Carozzi FM, Giorgi Rossi P, Matucci M, Iossa A, Del Mistro A, Maina G, Venturino E, Taddei GL, Giaimo MD.

Epidemiol Prev. 2016 May-Aug;40(3-4):150. doi: 10.19191/EP16.3-4.AD01.075. No abstract available.

7.

[Molecular biomarkers and early diagnosis of lung cancer: state of knowledge and future perspectives].

Carozzi FM, Bisanzi S.

Epidemiol Prev. 2016 Jan-Feb;40(1 Suppl 1):56-63. doi: 10.19191/EP16.1S1.P056.031. Italian.

8.

HPV testing for primary cervical screening: Laboratory issues and evolving requirements for robust quality assurance.

Carozzi FM, Del Mistro A, Cuschieri K, Frayle H, Sani C, Burroni E.

J Clin Virol. 2016 Mar;76 Suppl 1:S22-S28. doi: 10.1016/j.jcv.2015.10.025. Epub 2015 Nov 10. Review.

PMID:
26669512
9.

hr-HPV testing in the management of women with ASC-US+ and in the follow-up of women with cytological abnormalities and negative colposcopy. Recommendations of the Italian group for cervical cancer screening (GISCi).

Carozzi FM, Iossa A, Scalisi A, Sideri M, Andersson KL, Confortini M, Del Mistro A, Maina G, Ronco G, Raggi P, Schiboni ML, Zappa M, Giorgi Rossi P.

Epidemiol Prev. 2015 May-Jun;39(3 Suppl 1):84-90.

10.

The diffusion of screening programmes in Italy, years 2011-2012.

Zappa M, Carozzi FM, Giordano L, Sassatelli R, Federici A, Zorzi M, Federici A.

Epidemiol Prev. 2015 May-Jun;39(3 Suppl 1):5-8.

11.

Clinical impact of the analytical specificity of the hybrid capture 2 test: data from the New Technologies for Cervical Cancer (NTCC) study.

Gillio-Tos A, De Marco L, Carozzi FM, Del Mistro A, Girlando S, Burroni E, Frayle-Salamanca H, Giorgi Rossi P, Pierotti P, Ronco G; New Technologies for Cervical Cancer Screening Working Group.

J Clin Microbiol. 2013 Sep;51(9):2901-7. doi: 10.1128/JCM.01047-13. Epub 2013 Jun 26.

12.

Four-year results of low-dose CT screening and nodule management in the ITALUNG trial.

Lopes Pegna A, Picozzi G, Falaschi F, Carrozzi L, Falchini M, Carozzi FM, Pistelli F, Comin C, Deliperi A, Grazzini M, Innocenti F, Maddau C, Vella A, Vaggelli L, Paci E, Mascalchi M; ITALUNG Study Research Group.

J Thorac Oncol. 2013 Jul;8(7):866-75. doi: 10.1097/JTO.0b013e31828f68d6.

13.

HPV type distribution in invasive cervical cancers in Italy: pooled analysis of three large studies.

Giorgi Rossi P, Sideri M, Carozzi FM, Vocaturo A, Buonaguro FM, Tornesello ML, Burroni E, Mariani L, Boveri S, Zaffina LM, Chini F; HPV Prevalence Italian Working Group.

Infect Agent Cancer. 2012 Oct 12;7(1):26. doi: 10.1186/1750-9378-7-26.

14.

[Human Papilloma Virus (HPV), cervical cancer incidence and screening uptake: differences among Northern, Central and Southern Italy].

Giorgi Rossi P, Chini F, Borgia P, Guasticchi G, Carozzi FM, Confortini M, Angeloni C, Buzzoni C, Buonaguro FM; Gruppo di lavoro HPV Prevalenza.

Epidemiol Prev. 2012 Mar-Apr;36(2):108-19. Review. Italian.

PMID:
22706361
15.

Comparison of clinical performance of Abbott RealTime High Risk HPV test with that of hybrid capture 2 assay in a screening setting.

Carozzi FM, Burroni E, Bisanzi S, Puliti D, Confortini M, Giorgi Rossi P, Sani C, Scalisi A, Chini F.

J Clin Microbiol. 2011 Apr;49(4):1446-51. doi: 10.1128/JCM.02311-10. Epub 2011 Feb 16.

16.

Is human papillomavirus screening preferable to current policies in vaccinated and unvaccinated women? A cost-effectiveness analysis.

Accetta G, Biggeri A, Carreras G, Lippi G, Carozzi FM, Confortini M, Zappa M, Paci E.

J Med Screen. 2010;17(4):181-9. doi: 10.1258/jms.2010.010019.

PMID:
21258128
17.

Distribution of high and low risk HPV types by cytological status: a population based study from Italy.

Giorgi Rossi P, Chini F, Bisanzi S, Burroni E, Carillo G, Lattanzi A, Angeloni C, Scalisi A, Macis R, Pini MT, Capparucci P, Guasticchi G, Carozzi FM; Prevalence Italian Working Group.HPV.

Infect Agent Cancer. 2011 Jan 20;6:2. doi: 10.1186/1750-9378-6-2.

18.

The effect of self-sampled HPV testing on participation to cervical cancer screening in Italy: a randomised controlled trial (ISRCTN96071600).

Giorgi Rossi P, Marsili LM, Camilloni L, Iossa A, Lattanzi A, Sani C, Di Pierro C, Grazzini G, Angeloni C, Capparucci P, Pellegrini A, Schiboni ML, Sperati A, Confortini M, Bellanova C, D'Addetta A, Mania E, Visioli CB, Sereno E, Carozzi F; Self-Sampling Study Working Group.

Br J Cancer. 2011 Jan 18;104(2):248-54. doi: 10.1038/sj.bjc.6606040. Epub 2010 Dec 21.

19.

Prevalence of human papillomavirus types in high-grade cervical intraepithelial neoplasia and cancer in Italy.

Carozzi FM, Tornesello ML, Burroni E, Loquercio G, Carillo G, Angeloni C, Scalisi A, Macis R, Chini F, Buonaguro FM, Giorgi Rossi P; HPV Prevalence Italian Working Group.

Cancer Epidemiol Biomarkers Prev. 2010 Sep;19(9):2389-400. doi: 10.1158/1055-9965.EPI-10-0131.

20.

Prevalence of HPV high and low risk types in cervical samples from the Italian general population: a population based study.

Giorgi Rossi P, Bisanzi S, Paganini I, Di Iasi A, Angeloni C, Scalisi A, Macis R, Pini MT, Chini F, Carozzi FM; HPV Prevalence Italian Working Group.

BMC Infect Dis. 2010 Jul 20;10:214. doi: 10.1186/1471-2334-10-214.

Supplemental Content

Loading ...
Support Center